Is there a Bearish outlook for Seattle Genetics, Inc. (NASDAQ:SGEN) this week?

April 21, 2018 - By Marguerite Chambers

Seattle Genetics, Inc. (NASDAQ:SGEN) LogoInvestors sentiment increased to 1.23 in 2017 Q4. Its up 0.45, from 0.78 in 2017Q3. It improved, as 24 investors sold Seattle Genetics, Inc. shares while 67 reduced holdings. 44 funds opened positions while 68 raised stakes. 141.83 million shares or 1.14% more from 140.23 million shares in 2017Q3 were reported.
Barclays Public Limited Co invested in 0% or 17,316 shares. Kbc Group Nv reported 10,968 shares or 0.01% of all its holdings. Voya Invest Mngmt Ltd Liability Corporation reported 35,052 shares. Tributary Capital Management Lc stated it has 17,400 shares. Livforsakringsbolaget Skandia Omsesidigt holds 0.01% or 1,900 shares. Swiss Commercial Bank accumulated 0.02% or 367,200 shares. First Advsr L P reported 633,794 shares or 0.08% of all its holdings. Dekabank Deutsche Girozentrale has 84,337 shares. 26,039 are owned by Magnetar Ltd Co. Price T Rowe Md holds 7.80 million shares. Blackrock invested in 7.76 million shares or 0.02% of the stock. Vanguard Grp reported 0.02% stake. Trexquant Inv Ltd Partnership reported 17,397 shares or 0.1% of all its holdings. Sei Invs Com invested in 13,379 shares. 4,860 were accumulated by Manufacturers Life The.

Since December 11, 2017, it had 1 buying transaction, and 7 sales for $194.17 million activity. DRACHMAN JONATHAN G sold 10,457 shares worth $552,452. HIMES VAUGHN B had sold 5,000 shares worth $290,604. 3.85 million shares valued at $200.00 million were bought by BAKER BROS. ADVISORS LP on Thursday, February 1.

Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings Coverage

Among 11 analysts covering Seattle Genetics (NASDAQ:SGEN), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. Seattle Genetics had 20 analyst reports since October 23, 2017 according to SRatingsIntel. The company was upgraded on Friday, October 27 by Bank of America. Piper Jaffray maintained the stock with “Hold” rating in Friday, October 27 report. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Hold” rating given on Wednesday, November 8 by Oppenheimer. The firm has “Buy” rating given on Tuesday, March 20 by RBC Capital Markets. On Monday, October 30 the stock rating was maintained by JP Morgan with “Neutral”. The firm has “Buy” rating by H.C. Wainwright given on Friday, October 27. RBC Capital Markets maintained it with “Buy” rating and $71.0 target in Wednesday, January 31 report. J.P. Morgan upgraded Seattle Genetics, Inc. (NASDAQ:SGEN) on Wednesday, February 14 to “Buy” rating. The stock has “Overweight” rating by Morgan Stanley on Wednesday, March 21. The company was maintained on Friday, October 27 by RBC Capital Markets. Below is a list of Seattle Genetics, Inc. (NASDAQ:SGEN) latest ratings and price target changes.

21/03/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $69 New Target: $67 Maintain
20/03/2018 Broker: RBC Capital Markets Rating: Buy New Target: $73.0 Maintain
14/02/2018 Broker: J.P. Morgan Rating: Buy New Target: $66.0 Upgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Old Target: $60 Upgrade
07/02/2018 Broker: Needham Rating: Buy New Target: $74.0 Maintain
07/02/2018 Broker: Bank of America Old Rating: Neutral New Rating: Neutral Old Target: $70 New Target: $68 Maintain
07/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $77.0 Maintain
07/02/2018 Broker: SunTrust Rating: Hold New Target: $60.0 Maintain
01/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $75.0 Maintain
31/01/2018 Broker: RBC Capital Markets Rating: Buy New Target: $71.0 Maintain

The stock increased 0.22% or $0.11 during the last trading session, reaching $49.68. About 864,966 shares traded. Seattle Genetics, Inc. (NASDAQ:SGEN) has declined 20.48% since April 21, 2017 and is downtrending. It has underperformed by 32.03% the S&P500.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. The company has market cap of $7.86 billion. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. It currently has negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

Seattle Genetics, Inc. (NASDAQ:SGEN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.